Halfway there: The biggest type 1 diabetes prevention trial for babies reaches important milestone
One of Europe’s largest type 1 diabetes research cooperations has passed a significant milestone: The international platform GPPAD (“The Global Platform for the Prevention of Autoimmune Diabetes”) has successfully included 520 babies across Europe in the type 1 diabetes prevention trial POInT (Primary Oral Insulin Trial) – half of the targeted 1040 participants. The POInT study aims to train the i
